Investor Morningside Venture Investments Ltd
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Morningside Venture Investments Ltd . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-01-16 13D/A 6,254,545 616,502
2023-10-04 13D/A AMLX / Amylyx Pharmaceuticals, Inc. 4,618,846 2,313,227
2023-09-20 13G/A NAMS / NewAmsterdam Pharma Company N.V. 4,060,923
2023-08-17 13D/A AMLX / Amylyx Pharmaceuticals, Inc. 8,618,846 4,618,846
2023-08-17 13D/A KZR / Kezar Life Sciences, Inc. 6,254,545 6,254,545
2023-07-25 13D/A US39536G1058 / GREENLIGHT BIOSCIENCES HOLDINGS PBC A 16,919,155 0
2023-06-07 13D/A US39536G1058 / GREENLIGHT BIOSCIENCES HOLDINGS PBC A 13,857,931 16,919,155
2023-04-03 13D/A AMLX / Amylyx Pharmaceuticals, Inc. 9,302,142 8,618,846
2023-02-23 13D/A LMDXF / LumiraDx Limited 54,127,838 54,127,838
2023-02-14 13D LMDXF / LumiraDx Limited 19,495,148 54,127,838
2022-12-02 13G FLAC / Frazier Lifesciences Acquisition Corp - Class A 5,065,846
2022-09-30 13D/A AMLX / Amylyx Pharmaceuticals, Inc. 10,678,808 9,302,142
2022-02-16 13G/A AVIR / Atea Pharmaceuticals, Inc. 6,634,956 0
2022-02-14 13G LMDX / LumiraDx Limited 19,495,148
2022-02-14 13D US39536G1058 / GREENLIGHT BIOSCIENCES HOLDINGS PBC A 13,857,931
2022-02-14 13G/A APLS / Apellis Pharmaceuticals, Inc. 12,556,342 12,806,342
2022-01-25 13D AMLX / Amylyx Pharmaceuticals, Inc. 10,678,808
2021-11-22 13D/A MITO / Stealth BioTherapeutics Corp - ADR 540,133,192
2021-02-16 13G/A APLS / Apellis Pharmaceuticals, Inc. 12,015,802 12,556,342
2021-02-16 13G AVIR / Atea Pharmaceuticals, Inc. 6,634,956
2021-02-16 13D/A KZR / Kezar Life Sciences, Inc. 6,254,545 6,254,545
2020-06-16 13D/A KZR / Kezar Life Sciences, Inc. 6,109,052 6,254,545
2020-02-14 13D KZR / Kezar Life Sciences, Inc. 2,309,052 6,109,052
2020-01-16 13G/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 2,911,111 0
2019-05-24 13G/A KZR / Kezar Life Sciences, Inc. 2,309,052 2,309,052
2019-05-24 13G/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 2,911,111 2,911,111
2019-05-24 13G/A APLS / Apellis Pharmaceuticals, Inc. 12,015,802 12,015,802
2019-03-22 13G/A KZR / Kezar Life Sciences, Inc. 2,309,052 2,309,052
2019-03-22 13G/A NCNA / NuCana plc - Depositary Receipt (Common Stock) 2,911,111 2,911,111
2019-03-22 13G/A APLS / Apellis Pharmaceuticals, Inc. 12,015,802 12,015,802
2019-03-13 13G/A APLS / Apellis Pharmaceuticals, Inc. 11,574,626 12,015,802
2019-02-14 13G NCNA / NuCana plc - Depositary Receipt (Common Stock) 2,911,111
2019-02-14 13G APLS / Apellis Pharmaceuticals, Inc. 11,353,303 11,574,626
2019-02-14 13G KZR / Kezar Life Sciences, Inc. 2,309,052
2018-02-14 13G APLS / Apellis Pharmaceuticals, Inc. 11,353,303 11,353,303
2018-02-13 13G NCNA / NuCana plc - Depositary Receipt (Common Stock) 2,911,111
2018-02-13 13G APLS / Apellis Pharmaceuticals, Inc. 11,353,303